Numerous tyrosine kinase inhibitors (TKIs) with Hsp90 inhibition activity exert their actions by inhibiting cancer cells in the G1/S and G2/M cell cycle phases, and upregulation of p53. The gene discussed is TP53; the disease is cancer.